{"id":131538,"date":"2022-07-21T11:09:24","date_gmt":"2022-07-21T15:09:24","guid":{"rendered":"https:\/\/44.250.171.167\/?p=131538"},"modified":"2022-10-06T04:35:29","modified_gmt":"2022-10-06T08:35:29","slug":"gland-pharma-limited-q1-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/gland-pharma-limited-q1-fy23-earnings-conference-call-insights\/","title":{"rendered":"Gland Pharma Limited Q1 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Gland Pharma Ltd Q1 FY23 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/wKPiFWdsaFY?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Gland Pharma Limited (<a href=\"https:\/\/44.250.171.167\/symbol\/GLAND\/\">GLAND<\/a>) Q1 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Management Update:<\/strong><\/p>\n<ul>\n<li>GLAND said it is experiencing increased attrition and is ensuring the company builds enough resources, keeping in mind anticipated growth initiatives of the company.<\/li>\n<\/ul>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>Dheeresh Pathak from White Oak Capital asked about the profit share number for 1Q23. Ravi Shekhar CFO replied that it\u2019s about 10% of the revenue.<\/li>\n<\/ul>\n<ul>\n<li>Dheeresh Pathak from White Oak Capital enquired about capex guidance for FY23 and where the company will be spending the money. Ravi Shekhar CFO said that the capex guidance remains same of INR300 crore. In Pashamylaram, in the complex injectibles, GLAND is adding more API capacity. And a bag line needs to be added because of the increased demand.<\/li>\n<\/ul>\n<ul>\n<li>Dheeresh Pathak from White Oak Capital asked about any progress on the biologics CDMO from the last communication. Srinivas Sadu MD said there are four customer visits that have happened during the quarter and GLAND is discussing about the commercial terms. That&#8217;s where the status is.<\/li>\n<\/ul>\n<ul>\n<li>Dheeresh Pathak from White Oak Capital enquired when does the company expect to see the first revenue hit the P&amp;L from CDMO. Ravi Shekhar CFO said it\u2019s too early to comment at this point in time. Currently, GLAND will refrain from giving an exact time frame. But, capability-wise, team-wise, GLAND is all ready.<\/li>\n<\/ul>\n<ul>\n<li>Amey Chalke from Haitong Securities asked to quantify the impact on the supply shortages in the plant shutdown in 1Q23. Srinivas Sadu MD said that in US, GLAND lost about INR25 crores due to syringes. ROW about INR100 crore and domestic about INR40 crores.<\/li>\n<\/ul>\n<ul>\n<li>Amey Chalke from Haitong Securities asked about PFS suppliers and their struggling to cope up with the demand. Srinivas Sadu MD said that for ROW, GLAND is already qualifying other suppliers. For US, GLAND has enough supply commitments, so it\u2019s using a Chinese and a Italian supplier.<\/li>\n<\/ul>\n<ul>\n<li>Amey Chalke from Haitong Securities enquired about staff cost going up in 1Q23. Srinivas Sadu MD replied that what GLAND earlier referred was for one-time bonuses. But comparing now with 4Q22, it\u2019s the incremental staff cost which has come on account of additional head count and normal yearly increment.<\/li>\n<\/ul>\n<ul>\n<li>Amey Chalke from Haitong Securities also asked that if it can be assumed that INR98 crore to be a normalized base for staff cost. Srinivas Sadu MD said it can be assumed as the normalized cost.<\/li>\n<\/ul>\n<ul>\n<li>Sudarshan Padmanabhan from JM Financial asked about shortage and how do GLAND see things easing up from 2Q23. Srinivas Sadu MD said that while syringes is a major impact that has happened, there are also issues around four or five products where GLAND has filed alternative tubing or filters with FDA.<\/li>\n<\/ul>\n<ul>\n<li>Sudarshan Padmanabhan from JM Financial asked about demand with respect to volumes. Srinivas Sadu MD replied that demand is there. Enoxa on a QonQ basis GLAND sold almost three times in 1Q23. Ketorolac is almost 90% growth. So in a way, GLAND is not seeing demand dropping.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Gland Pharma Limited (GLAND) Q1 FY23 Earnings Concall Management Update: GLAND said it is experiencing increased attrition and is ensuring the company builds enough resources, keeping in mind anticipated growth initiatives of the company. Q&amp;A Highlights: Dheeresh Pathak from White Oak Capital asked about the profit share number for 1Q23. Ravi Shekhar [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Gland Pharma Limited Q1 FY23 Earnings Conference Call Insights #GLAND #Q1 #FY23","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[1115],"class_list":["post-131538","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":139024,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-limited-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":131538,"position":0},"title":"Gland Pharma Limited Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"January 24, 2023","format":false,"excerpt":"Key highlights from Gland Pharma Limited (GLAND) Q3 FY23 Earnings Concall Management Update: [00:06:08] GLAND said the insulin line is in the process of ramping up post line improvements. The company expects to close Cenexi acquisition by March-April 2023 and focus on leveraging synergies between businesses. [00:06:24] GLAND also stated\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":135214,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-limited-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":131538,"position":1},"title":"Gland Pharma Limited Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"October 27, 2022","format":false,"excerpt":"https:\/\/youtu.be\/4X77Cs34eLo Key highlights from Gland Pharma Limited (GLAND) Q2 FY23 Earnings Concall Management Update: [00:02:23] GLAND said it saw improvement in supplies in 2H23 and have better visibility on key material supplies going forward. Q&A Highlights: [00:15:19] Neha Manpuria of BofA enquired about the US numbers, the pricing pressure and\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":135486,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-limited-gland-q2-fy23-earnings-concall-transcript\/","url_meta":{"origin":131538,"position":2},"title":"Gland Pharma Limited (GLAND) Q2 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"October 26, 2022","format":false,"excerpt":"Gland Pharma Limited (NSE:GLAND) Q2 FY23 Earnings Concall dated Oct. 26, 2022 Corporate Participants: Sumanta Bajpayee\u00a0\u2014\u00a0Vice President, Corporate Finance and Investor Relations Srinivas Sadu\u00a0\u2014\u00a0Managing Director & Chief Executive Officer Ravi Shekhar Mitra\u00a0\u2014\u00a0Chief Financial Officer Analysts: Neha Manpuria\u00a0--\u00a0Bank of America -- Analyst Dheeresh Pathak\u00a0--\u00a0White Oak Capital -- Analyst Sameer Baisiwala\u00a0--\u00a0Morgan Stanley\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"stock earnings conference call transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":131543,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-limited-gland-q1-fy23-earnings-concall-transcript\/","url_meta":{"origin":131538,"position":3},"title":"Gland Pharma Limited (GLAND) Q1 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"July 21, 2022","format":false,"excerpt":"Gland Pharma Limited (NSE: GLAND) Q1 FY23 Earnings Concall dated Jul. 20, 2022 Corporate Participants: Sumanta Bajpayee\u00a0--\u00a0Vice President, Corporate Finance and Investor Relations Srinivas Sadu\u00a0--\u00a0Managing Director & Chief Executive Officer Ravi Shekhar Mitra\u00a0--\u00a0Chief Financial Officer Analysts: Tarang Agarwal\u00a0--\u00a0Old Bridge Capital -- Analyst Dheeresh Pathak\u00a0--\u00a0WhiteOak Capital -- Analyst Amey Chalke\u00a0--\u00a0Haitong Securities\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":132911,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-limited-gland-q1-fy23-earnings-concall-transcript-2\/","url_meta":{"origin":131538,"position":4},"title":"Gland Pharma Limited (GLAND) Q1 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"July 20, 2022","format":false,"excerpt":"Gland Pharma Limited\u00a0(NSE:GLAND) Q1 FY23 Earnings Concall dated Jul. 20, 2022 Corporate Participants: Sumanta Bajpayee -- Vice President, Corporate Finance and Investor Relations Srinivas Sadu -- Managing Director & Chief Executive Officer Ravi Shekhar Mitra -- Chief Financial Officer Analysts: Tarang Agarwal -- Old Bridge Capital -- Analyst Dheeresh Pathak\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":146646,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-gland-pharma-limited-for-q4-fy23\/","url_meta":{"origin":131538,"position":5},"title":"Earnings Summary Of Gland Pharma Limited For Q4 FY23","author":"Hardik Bhandare","date":"May 18, 2023","format":false,"excerpt":"Gland Pharma Limited specializes in the production of sterile injectable formulations, including vials, ampoules, pre-filled syringes, and lyophilized products. The company's focus on sterile injectables positions it as a key player in critical care, oncology, ophthalmology, and other therapeutic areas. Gland Pharma's state-of-the-art manufacturing facilities adhere to international quality standards,\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/131538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=131538"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/131538\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=131538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=131538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=131538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}